Living Conditions and Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier:
NCT01626950
First received: June 21, 2012
Last updated: March 3, 2014
Last verified: March 2014

June 21, 2012
March 3, 2014
May 2012
November 2013   (final data collection date for primary outcome measure)
The odds ratio for having a stage I-II diagnosis versus a stage III-IV diagnosis according to EPICE score category (social fragility versus no social fragility). [ Time Frame: Baseline (Day 0; cross-sectional study) ] [ Designated as safety issue: No ]
The main criterion is the estimation of the link (odds ratio) between the precariousness defined by the score SPICE (2 groups: precarious and insecure) and stage at diagnosis (2 groups: CAS: stages 1 or 2 the "good prognosis "versus the witnesses: stage 3 or 4 bad prognosis).
Same as current
Complete list of historical versions of study NCT01626950 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Living Conditions and Breast Cancer
Living Conditions and Breast Cancer

The main objective of this study is to estimate of the link (odds ratio) between the precariousness defined by the score SPICE (2 groups: precarious and insecure) and stage at diagnosis (2 groups: CAS: stages 1 or 2 the "good prognosis "versus the witnesses: stage 3 or 4 bad prognosis).

Our secondary objectives include:

  • To study the link between cancer stage at diagnosis and diverse parameters describing living conditions
  • To construct a new score for social fragility based on new data collected in this study, and to compare this score with the EPICES score
  • To study patient quality of life at study baseline
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

This study is a case-control study concerning the female population suffering from breast cancer in the Herault department of France. Only invasive cancers are taken into account. For each case, we will have at least 2 controls, matched according to age +- 2 years.

Breast Neoplasms
Not Provided
  • Cases - Stage III-IV breast cancer
    The women in this group have been diagnosed with stage III-IV incident cancer.
  • Controls: Stage I-II breast cancer
    The women in this group have been diagnosed with stage I-II incident cancer.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
684
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria (for cases):

  • Patient has been correctly informed about the study, and agrees to participate
  • The patient must be insured or beneficiary of a health insurance plan
  • Incident breast cancer cases (diagnosis based on pathology) excluding sarcoma, classifiable as stage III-IV, surgical cases

Inclusion Criteria (for controls):

  • Patient has been correctly informed about the study, and agrees to participate
  • The patient must be insured or beneficiary of a health insurance plan
  • Incident breast cancer cases (diagnosis based on pathology) excluding sarcoma, classifiable as stage I-II, surgical cases

Exclusion Criteria (for cases and controls):

  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient is pregnant, parturient, or breastfeeding
  • The patient is opposed to study participation
  • Women not able to answer a questionnaire due to language barriers or due to vascular or degenerative cerebral dysfunction
  • It is impossible to correctly inform the patient
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01626950
AO/INCA/2011/JPD, 2012-A00377-36
No
Centre Hospitalier Universitaire de Nīmes
Centre Hospitalier Universitaire de Nīmes
Not Provided
Principal Investigator: Jean Pierre Daurès, MD PhD Centre Hospitalier Universitaire de Nîmes
Centre Hospitalier Universitaire de Nīmes
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP